Literature DB >> 3296901

Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases.

J R Berger, B Kaszovitz, M J Post, G Dickinson.   

Abstract

Progressive multifocal leukoencephalopathy, a common complication of infections with human immunodeficiency virus (HIV), occurs in as many as 3.8% of patients with the acquired immunodeficiency syndrome (AIDS). We report 16 cases and review 12 previously reported cases of progressive multifocal leukoencephalopathy associated with HIV infection. This illness was the presenting manifestation of HIV infection in 8 cases. Limb weakness, gait abnormalities, visual loss, aand altered mental status were the commonest initial complaints. Computed tomography of the brain frequently showed hypodense, nonenhancing white matter lesions. Magnetic resonance imaging was more sensitive than computed tomography in detecting lesions. Cerebrospinal fluid analysis and electroencephalography were nondiagnostic. Impaired cell-mediated immunity was typically noted, even in the absence of other immunodeficiency-associated illnesses. Death occurred within 10 days to 18 months of the onset of symptoms in 22 patients. However, 4 patients remain alive at 3 to 23 months; of these 4, 2 have had significant improvement without treatment. Various therapies were unsuccessful.

Entities:  

Mesh:

Year:  1987        PMID: 3296901     DOI: 10.7326/0003-4819-107-1-78

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  120 in total

Review 1.  Epidemiological evidence and molecular basis of interactions between HIV and JC virus.

Authors:  J R Berger; A Chauhan; D Galey; A Nath
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients.

Authors:  V Dubois; H Dutronc; M E Lafon; V Poinsot; J L Pellegrin; J M Ragnaud; A M Ferrer; H J Fleury
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

3.  Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.

Authors:  J Kuhle; R Gosert; R Bühler; T Derfuss; R Sutter; O Yaldizli; E-W Radue; C Ryschkewitsch; E O Major; L Kappos; S Frank; H H Hirsch
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

Review 4.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

5.  Progressive Multifocal Leukoencephalopathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

6.  JC Virus Infection After Transplantation: Beyond the Classic Progressive Multifocal Leukoencephalopathy?

Authors:  Supha Kijpittayarit; Raymund R Razonable
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-01

Review 7.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

8.  Cohort Profile: Recruitment cohorts in the neuropsychological substudy of the Multicenter AIDS Cohort Study.

Authors:  James T Becker; Lawrence A Kingsley; Samantha Molsberry; Sandra Reynolds; Aaron Aronow; Andrew J Levine; Eileen Martin; Eric N Miller; Cynthia A Munro; Ann Ragin; Ned Sacktor; Ola A Selnes
Journal:  Int J Epidemiol       Date:  2014-04-24       Impact factor: 7.196

9.  JC virus-induced changes in cellular gene expression in primary human astrocytes.

Authors:  Sujatha Radhakrishnan; Jessica Otte; Sahnila Enam; Luis Del Valle; Kamel Khalili; Jennifer Gordon
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Identification and characterization of a novel GGA/C-binding protein, GBP-i, that is rapidly inducible by cytokines.

Authors:  G V Raj; K Khalili
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.